Immutep Ltd ADR
Price & Volume
Stats
See more52W Range | $2.98-$66.38 |
Market Cap | $22M |
Shares Short | 33,547 |
Financials
See moreRevenue (12 Mos) | $19.9M |
Revenue Growth (YoY) | 633.5% |
Gross Profit (12 Mos) | -$72M |
Diluted EPS | -$7.30 |
News
See moreYahoo Finance • 13 days ago
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Yahoo Finance • 3 months ago
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
Yahoo Finance • 4 months ago
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Yahoo Finance • 4 months ago
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
About
CEO | Mr. Marc Voigt |
CFO | Mr. Marc Voigt |
Address | Australia Square, Sydney, NSW, Australia, 2000 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 0 |